The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial.
Alessandro Passardi
No relevant relationships to disclose
Emanuela Scarpi
No relevant relationships to disclose
Luigi Cavanna
No relevant relationships to disclose
Annalisa Fontana
No relevant relationships to disclose
Bernadette Vertogen
No relevant relationships to disclose
Silvia Ruscelli
No relevant relationships to disclose
Emiliano Tamburini
No relevant relationships to disclose
Angela Ragazzini
No relevant relationships to disclose
Giovanni Luca Frassineti
No relevant relationships to disclose
Oriana Nanni
No relevant relationships to disclose
Dino Amadori
No relevant relationships to disclose